Cardinal Health company profile
Company profile
Cardinal Health has 58,788 employees and is headquartered in Dublin, United States.
Customers of this US company include hospital and pharmacy operators, physicians, surgery centers, clinical laboratories and patients who receive care at home, and its activity is concentrated in the United States. Its operations are organized into two segments, one covering pharmaceuticals and specialty solutions and the other global medical products and distribution. It distributes branded, generic and over-the-counter pharmaceuticals, runs pharmacies, repackages generic drugs and supplies pharmaceutical manufacturers with services for specialty products. Under its own brand it manufactures gloves, syringes, wound care items, surgical drapes, suction systems and radiopharmaceuticals, and it also offers supply chain services and procedure kits.
In the fiscal year ended June 2026, revenue reached $254.2 billion, up 14.2% from the prior year, and net income was $1.7 billion. About 99.4% of revenue came from the United States. The company had 58,788 employees, was incorporated in 1979 and is headquartered in Dublin, Ohio.
Company facts
- Sector
- Healthcare
- Industry
- Medical Distribution
- Country
- United States
- Headquarters
- 7000 Cardinal Place, 43017, Dublin
- Employees
- 58,788
- Chief executive
- Jason Hollar
- Founded
- 1979
- Fiscal year
- July - June
- Listing
- CAH · NYSE
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US14149Y1082
- Website
- cardinalhealth.com
Cardinal Health and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Cardinal HealthCAH | United States | $64.97B | 58,788 | 1.3% | 36.4 |
| CencoraCOR | United States | $68.11B | 47,000 | 1.4% | 20.0 |
| McKessonMCK | United States | $126.04B | 41,600 | 1.6% | 28.2 |
| Henry ScheinHSIC | United States | $9.17B | 25,000 | 5.8% | 22.7 |
| Sigma HealthcareSIG | Australia | $22.55B | — | 9.2% | 48.3 |
| Sinopharm Group Ltd H1099 | Hong Kong SAR China | $6.68B | 94,910 | 3.0% | 6.51 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
